Effect of Intensive Blood Pressure Control on Kidney Outcomes
- 25 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (2) , 213-223
Abstract
Background: Intensive BP lowering in the Systolic Blood Pressure Intervention Trial (SPRINT) produced acute decreases in kidney function and higher risk for AKI. We evaluated the effect of intensive BP lowering on long-term changes in kidney function using trial and outpatient electronic health record (EHR) creatinine values. Methods: SPRINT data were linked with EHR data from 49 (of 102) study sites. The primary outcome was the total slope of decline in eGFR for the intervention phase and the post-trial slope of decline during the observation phase using trial and outpatient EHR values. Secondary outcomes included a ≥30% decline in eGFR to 2 and a ≥50% decline in eGFR or kidney failure among participants with baseline eGFR ≥60 and 2, respectively. Results: EHR creatinine values were available for a median of 8.3 years for 3041 participants. The total slope of decline in eGFR during the intervention phase was −0.67 ml/min per 1.73 m2 per year (95% confidence interval [CI], −0.79 to −0.56) in the standard treatment group and −0.96 ml/min per 1.73 m2 per year (95% CI, −1.08 to −0.85) in the intensive treatment group (P < 0.001). The slopes were not significantly different during the observation phase: −1.02 ml/min per 1.73 m2 per year (95% CI, −1.24 to −0.81) in the standard group and −0.85 ml/min per 1.73 m2 per year (95% CI, −1.07 to −0.64) in the intensive group. Among participants without CKD at baseline, intensive treatment was associated with higher risk of a ≥30% decline in eGFR during the intervention (hazard ratio, 3.27; 95% CI, 2.43 to 4.40), but not during the postintervention observation phase. In those with CKD at baseline, intensive treatment was associated with a higher hazard of eGFR decline only during the intervention phase (hazard ratio, 1.95; 95% CI, 1.03 to 3.70). Conclusions: Intensive BP lowering was associated with a steeper total slope of decline in eGFR and higher risk for kidney events during the intervention phase of the trial, but not during the postintervention observation phase.Keywords
Funding Information
- Division of Intramural Research (R01HL136679)
- National Institute on Aging (R01AG055606)
- Division of Intramural Research (R01HL136679)
- National Institute on Aging (R01AG055606)
This publication has 15 references indexed in Scilit:
- Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR StudyKidney360, 2022
- Final Report of a Trial of Intensive versus Standard Blood-Pressure ControlNew England Journal of Medicine, 2021
- Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical PracticeJAMA Internal Medicine, 2020
- Effect of Blood Pressure Control on Long‐Term Risk of End‐Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney DiseaseJournal of the American Heart Association, 2019
- Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical SimulationJournal of the American Society of Nephrology, 2019
- Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure ReductionAnnals of Internal Medicine, 2018
- Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)American Journal of Kidney Diseases, 2018
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisThe Lancet, 2016
- A Randomized Trial of Intensive versus Standard Blood-Pressure ControlNew England Journal of Medicine, 2015
- The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease StudyAnnals of Internal Medicine, 2005